Teva Pharmaceutical Industries and Heptares will collaborate to develop new Heptares-discovered small-molecule calcitonin gene-related peptide (CGRP) antagonists for migraine, the companies said today.

The deal could generate up to $410 million plus for Heptares, with Teva in return receiving worldwide development and commercial rights to new CGRP antagonists co-developed by the companies.

Teva agreed to pay Heptares $10 million upfront, and potentially up to $400 million in payments tied to achieving research, development, and commercialization milestones. Heptares is also eligible to receive royalties on net sales of products resulting from the alliance, the companies said.

“We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody,” Michael Hayden, M.D., Ph.D., Teva’s president of global R&D and CSO, said in a statement.